Gene Therapy Injection Restores Hearing in Deaf Patients Within Weeks
Single injection of gene therapy restored hearing in all 10 patients with genetic deafness, with some showing improvement in just one month.
Summary
Researchers successfully restored hearing in people born deaf using a single gene therapy injection. The treatment delivered a working copy of the OTOF gene directly into the inner ear of 10 patients aged 1-24. All participants showed hearing improvement within six months, with most beginning to recover hearing within one month. Children aged 5-8 showed the most dramatic results, with one seven-year-old girl regaining nearly full hearing and having conversations with her mother just four months after treatment. The therapy was well-tolerated with no serious side effects observed during the 6-12 month follow-up period.
Detailed Summary
A groundbreaking gene therapy study has successfully restored hearing in people born with genetic deafness, offering hope for millions worldwide with hereditary hearing loss. This represents a major breakthrough in treating congenital deafness through genetic intervention rather than traditional hearing aids or cochlear implants.
Researchers at Karolinska Institutet treated 10 patients aged 1-24 with mutations in the OTOF gene, which prevents production of otoferlin protein essential for transmitting sound signals from the inner ear to the brain. Using a synthetic virus as a delivery vehicle, they injected a working copy of the gene directly through the cochlea's round window membrane.
Results were remarkable: all patients showed hearing improvement, with average sound detection improving from 106 decibels to 52 decibels after six months. Most patients began recovering hearing within one month. Children aged 5-8 responded most dramatically, with one seven-year-old achieving near-normal hearing and conversational ability within four months. Even adult patients experienced meaningful improvements.
The treatment proved safe with only minor decreases in white blood cells as the primary side effect. No serious adverse reactions occurred during the 6-12 month follow-up period. This safety profile is crucial for potential widespread application.
While currently limited to OTOF gene mutations, researchers are expanding to target more common deafness genes like GJB2 and TMC1. This could eventually help millions with genetic hearing loss, though the durability of effects requires longer-term study.
Key Findings
- Single gene therapy injection restored hearing in all 10 patients with OTOF gene mutations
- Most patients began hearing recovery within one month of treatment
- Children aged 5-8 showed most dramatic improvement, some achieving near-normal hearing
- Average sound detection improved from 106 to 52 decibels after six months
- Treatment was safe with no serious side effects during 6-12 month follow-up
Methodology
This is a research news report from ScienceDaily covering a study published in Nature Medicine. The source is credible, involving Karolinska Institutet researchers. Evidence is based on a small clinical trial with 10 patients across multiple hospitals in China.
Study Limitations
Very small sample size of 10 patients limits generalizability. Follow-up period of 6-12 months is insufficient to assess long-term durability. Treatment is currently limited to specific OTOF gene mutations, not applicable to other causes of deafness.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.